Monopar Therapeutics shares are trading lower after gaining Thursday. The stock was volatile yesterday after the company entered into an agreement with Alexion, AstraZeneca Rare Disease, for an exclusive worldwide license to ALXN-1840 for Wilson disease.
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics shares are experiencing volatility following an agreement with Alexion, AstraZeneca Rare Disease, for an exclusive worldwide license to ALXN-1840 for Wilson disease.
October 25, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Monopar Therapeutics shares are trading lower after a volatile session due to a new licensing agreement with Alexion, AstraZeneca Rare Disease.
The stock is reacting to the news of a licensing agreement with Alexion, which initially caused a rise in share price but is now trading lower. This suggests investor uncertainty or profit-taking after the initial positive reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100